Brii Biosciences Limited
HKSE: 2137.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhi Hong
- Employees
- 98
- Headquarters
- Beijing, China
- IPO year
- 2021
- Market cap
- HK$966.4M
- Website
- https://www.briibio.com
Loading 2137…
Loading profile data…Frequently asked questions about 2137
What does Brii Biosciences Limited (2137.HK) do?
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanis...
Where does 2137.HK trade?
Brii Biosciences Limited (2137.HK) trades on the Hong Kong Stock Exchange.
What sector is 2137.HK in?
Brii Biosciences Limited (2137.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Brii Biosciences Limited?
Zhi Hong is the chief executive officer of Brii Biosciences Limited (2137.HK).
Where is Brii Biosciences Limited headquartered?
Brii Biosciences Limited is headquartered in China.
Does 2137.HK pay a dividend?
Brii Biosciences Limited (2137.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2137.HK go public?
Brii Biosciences Limited (2137.HK) completed its initial public offering in 2021.